Aromatase Inhibitors: New Drug of Choice for Induction of Ovulation

M SIDDQUIP, N MAHMUDP, MR BEGUMC, T A CHOWDHURYD

Summary:
Anovulationaccountsforaround20%casesofinfertility even when other fertility factors are normal. Clomiphene Citrate (CC), the oral anti-estrogen has long been used as the first line drug for induction of ovulation. Clomiphene is associated with a high ovulation (60-80%) but relatively poor pregnancy rate (30-40%). CC leads to long lasting estrogen receptor depletion. Because of its long half-life (2 weeks), CC possibly exerts a negative feedback effect on the cervical mucus and endometrial development with subsequent implantation failure. The aromatase inhibitor letrozole (originally approved for use in postmenopausal women with breast cancer to suppress estrogen production) is now increasingly being used by fertility specialists worldwide for ovulation induction. With a half-life of around 45 hours, letrozole possibly avoids the adverse effects of CC on endometrium. Preliminary trials have shown impressive prospects of aromatase inhibitor letrozole for induction of ovulation (even in CC resistant cases) with satisfactory pregnancy rates. Letrozole is now being marketed by our local pharmaceutical companies. Though largescale randomized controlled trials are not yet available, letrozole holds a very promising chance of replacing CC in near future.

Introduction:
Infertility is thought to affect 10 to 15% of couples but this percentage may be an underestimate1,2. The inability to conceive carries a hidden stigma of shame and secrecy for some couples, whereas others are never enumerated because they cannot afford to seek medical treatment3. Failure to seek management, investigation and treatment compounds the tragedy of infertility because simple, inexpensive therapeutic options may be appropriate for anovulatory infertility or even in expectant management of unexplained infertility. In a study on rural population of Bangladesh, 3.2% of married women of reproductive age have primary infertility and 3% have secondary infertility4. Majority of infertile women (40%) believed this to be their fate and 33% accused themselves for infertility4.

In a review, Homberg and Insler5 concluded that taking into account efficacy, complication rates and cost of infertility treatment, women with hypogonadotrophic hypogonadism or polycystic ovary syndrome(PCOS) should be offered acceptable methods of ovulation induction and that couples with ‘unexplained’ or ‘multifactorial subfertility’ should be exposed to controlled ovarian hyperstimulation with intrauterine insemination and only after the failure of these therapies should be offered in vitro fertilization(IVF).

Ovulatory dysfunction is one of the most common causes for reproductive difficulty in otherwise fertile couples. Once successful ovulation is achieved, fertility is often restored. Ovarian stimulation during infertility treatment is used either alone or in conjunction with intrauterine insemination and assisted reproductive technologies. At present, the two main medications used for induction of ovulation include an oral antiestrogen, such as clomiphene citrate (CC), and an injectable gonadotropins,
predominantly recombinant follicle stimulating hormone (FSH)\textsuperscript{6-9}. In specific situations, there are other less frequently used treatments to induce or restore ovulation, such as pulsatile administration of gonadotropin-releasing hormone (GnRH) for women with hypothalamic anovulation\textsuperscript{10}, dopaminergic agonists for women with hyperprolactinemic anovulation\textsuperscript{11,12} and insulin sensitizers for women with PCOS\textsuperscript{13}.

Both clomiphene citrate (CC) and gonadotropins are associated with various disadvantages that include risk of life threatening ovarian hyperstimulation syndrome, high order multiple pregnancy, lower pregnancy rate despite high ovulatory rate (especially for clomiphene citrate) and high expenses with parenteral administration requiring intensive monitoring (FSH treatment)\textsuperscript{14}.

Clomiphene citrate (CC) is the most commonly used drug for the induction and augmentation of ovulation. However 20-25% women are resistant to clomiphene citrate\textsuperscript{14}. In addition, clinical data reveal a discrepancy between ovulation and conception rates between CC treatment, and a higher than expected incidence of miscarriage in conception cycles. These observations have been attributed to the peripheral anti-estrogenic mechanism of action of CC that involves long lasting estrogen receptor depletion in the endometrium and cervix\textsuperscript{14}.

In spite of high ovulation rate, clomiphene is associated with low pregnancy rate with resistance to 20-25% of women. In CC failures, expensive gonadotropin injections are the next treatment option but, especially in polycystic ovary syndrome, are associated with increased risk of ovarian hyperstimulation requiring intensive monitoring. So, obviously a cheap oral agent is preferred that can induce ovulation in resistant cases without extensive monitoring and having less side effects on the endometrium.

**Letrozole : The aromatase inhibitor**

**Mode of Action**

Letrozole belongs to a new group of very potent, non-steroidal, selective reversible third generation aromatase inhibitor developed for postmenopausal breast cancer therapy\textsuperscript{14}. Letrozole inhibits the conversion of adrenally generated androstenedione to estrone or estradiol by aromatase enzyme in peripheral tissues. It acts by competitive binding to the haem of cytochrome P450 subunit of the aromatase enzyme and interrupts the metabolism of estrogen resulting in a decrease level of estrogen in the body. As a negative feedback mechanism, the pituitary gland produces follicle stimulating hormone (FSH) leading to ovulation or superovulation. Therefore, letrozole generally mimics the action of CC without depletion of estrogen receptors when administered early in the menstrual cycle\textsuperscript{14}. Because of the much shorter life span (2 days) and absence of estrogen receptor binding, it possibly avoids the antiestrogenic effects associated with CC\textsuperscript{14}.

**Metabolism and side effects**

Letrozole has no significant active metabolites. It is completely absorbed after oral administration and has a mean terminal half-life of 45 hours (range 30-60 hours). It is cleared from the systemic circulation mainly by the liver.

Letrozole generally is well tolerated; the most common treatment-related adverse effects are hot flushes, nausea, and hair thinning. In the trial of extended adjuvant therapy, adverse events reported more frequently with letrozole than placebo were hot flushes, arthralgia, myalgia and arthritis, but cessation of letrozole was no more frequent than placebo in this double-blind trial. A greater number of new diagnosis of osteoporosis occurred among women receiving letrozole, but the long term effects on bone mineral density or lipid metabolism are yet to be determined.

**Is it teratogenic?**

Over the recent years, letrozole has been studied at the University of Toronto as a fertility drug with satisfying results\textsuperscript{15}. Their studies found that the drug appears to be completely eliminated from the body within a few days of the last tablet. So far there is no evidence that this drug has any harmful effects on the developing fetus. It therefore appears to be safe as a fertility drug.

In 2005, some concern was raised as a result of an abstract of a study that compared 150 babies born to women who had used letrozole with 36,005 babies...
born to low-risk pregnant women\textsuperscript{16}. The results of this study, which had several gross methodological drawbacks, suggested that letrozole might increase the risk of cardiac and bone anomalies\textsuperscript{16}. Since that initial report, however, several full-length studies have not shown an increased risk for congenital malformations following the use of letrozole to induce ovulation. A study published in 2006 examined 514 babies born to mother who had used letrozole to conceive, and compared them with 397 babies born to mothers who had conceived using clomiphene citrate\textsuperscript{17}. There were no increased rates of major and minor malformations beyond what would be expected in the general population (1-3\%)\textsuperscript{17}. Additionally, the number of cardiac anomalies in the letrozole group (0.2\%) was slightly lower than that of the general population\textsuperscript{17}.

Letrozole is approved by the United States Food and Drug Administration (FDA) for the treatment of local or metastatic breast cancer that is hormone receptor positive in postmenopausal women. Infertility specialists have been using this drug for ovulation induction since 2001. However, like many other drugs (eg. misoprostol), induction of ovulation by letrozole is an ‘off-label’ indication because it is not marketed for use as a fertility drug\textsuperscript{15}.

**Recent Studies on letrozole**

Over the last few years, several published studies, both controlled and noncontrolled, compared clomiphene citrate and letrozole, either alone or in combination with gonadotropins, for ovulation induction or augmentation\textsuperscript{18}. These studies found letrozole as effective as clomiphene in inducing ovulation, with the major advantage of absence of any anti-estrogenic adverse effects. Patients treated with letrozole demonstrated low estrogen production per developing follicle resulting in more physiological estrogen levels around the time of ovulation and good pregnancy rates with a lower incidence of multiple pregnancies than with clomiphene\textsuperscript{18}. When combined with gonadotropins, letrozole reduces the dose of gonadotropins required for optimal follicular recruitment and improve the response to gonadotropin stimulation in poor responders\textsuperscript{19}. However, a recent study involving 438 PCOS patients did not show any advantage of letrozole over CC as a first line treatment for induction of ovulation in PCOS patients\textsuperscript{20}. A group of Turkish researchers concluded that letrozole and CC have comparable effectiveness in ovulatory patients with unexplained infertility\textsuperscript{21}. A small study involving 22 patients from the University of Toronto showed the supremacy of letrozole in ovulation induction in patients with an inadequate response to Clomiphene citrate\textsuperscript{22}. This hypothesis is supported by another study in a tertiary referral infertility clinic at Dhaka involving 35 infertile patients non responsive to CC which showed a high success rate (77.77\%) for follicular development using letrozole\textsuperscript{23}. Another survey also reported a successful induction (62\%) in PCOS patients using letrozole previously treated with Clomiphene citrate\textsuperscript{24}. Researchers from a university hospital in Greece concluded that ovulation induction with letrozole is associated with acceptable success rate compared with gonadotropin with significant less cost, risks and patient inconvenience\textsuperscript{25}. In patients who failed to conceive with CC, gonadotrophins have a higher pregnancy rate for ovulation induction than letrozole\textsuperscript{26}. However, pregnancy rates were high enough with letrozole to justify its use\textsuperscript{26}. Compared to CC in gonadotrophin combined Intrauterine Insemination (IUI) cycles, number of mature follicles and serum estradiol levels on the day of hCG were significantly lower in the letrozole group. No significant differences were found in endometrial thickness measured on the day of hCG but the pregnancy rate was higher in letrozole group\textsuperscript{27}. Comparing the endocrinological environment, significantly lower estradiol concentrations and fewer follicles were observed in cycles stimulated with 2.5 mg letrozole compared to 100 mg of CC from day 3 to day 7 of the cycle\textsuperscript{28}. However, the administration of 50 mg CC was found superior to 2.5 mg letrozole for superovulation induction in Asian women with normal ovulation\textsuperscript{29}. Similar to CC, aromatase inhibition by letrozole reduces FSH dose required for controlled ovarian hyperstimulation (COH) without the undesirable antiestrogenic effects sometimes seen with CC\textsuperscript{29}. Letrozole appears to constitute a good alternative to CC in patients with unexplained infertility undergoing gonadotrophin stimulated COH cycles combined with IUI therapy\textsuperscript{30}. It also seems to be an acceptable alternative to CC as an ovulation
inducing agent in patients with PCOS. The third generation aromatase inhibitor letrozole is as effective as or superior to CC in ovulation induction and in superovulation. Unlike CC, they do not carry an antiestrogenic effect on the endometrium. Letrozole blocks estrogen production, not estrogen receptors, and would therefore be expected to produce superior conception rates and less multiple pregnancies. Letrozole has got better ovulation and pregnancy rate in comparison to clomiphene citrate in patients with PCOS. It also seems to be an effective alternative as a low-cost IVF protocol in women with poor response to gonadotrophins. Letrozole is yet to undergo further large, robust clinical trials in order to fulfill these promises as a feasible alternative to CC in this role, but some preliminary trials have shown at least equality and some superiority.

Conclusion
Clinical utilization of ovarian stimulation to facilitate the ability of a couple to conceive has not only provided a valuable therapeutic approach, but has also yielded extensive information on the physiology of ovarian follicular recruitment, endometrial receptivity and early embryo competency. For the last 40 years, the first line of treatment for induction of ovulation has been clomiphene citrate. It is a safe, cheap oral agent but is known to have relatively common antiestrogenic endometrial and cervical mucous side effects that could prevent pregnancy in the face of successful ovulation. Infertility specialists have been increasingly using letrozole for induction. Because of the recent acceptance of the concept of using aromatase inhibitors for ovulation induction, a few small controlled studies were identified, and the rest were pilot or preliminary comparisons. Based on these studies, it appears that aromatase inhibitor letrozole is as effective as clomiphene in inducing ovulation, results in lower serum estrogen concentrations, and is associated with a good pregnancy rate with a lower incidence of multiple pregnancies than clomiphene citrate. Letrozole reduces the dose of FSH required for optimal follicular recruitment and improves the response to FSH in poor responders. So, preliminary evidence is suggesting that letrozole may replace clomiphene citrate in the future because of similar efficacy with a reduced side effect profile. Although worldwide experience with letrozole for ovulation induction is increasing, at present, definitive large scale studies in the form of randomized controlled trials comparing clomiphene citrate with letrozole are lacking.

References:

16. Biljan MM, Hemmings R, Brassand N. The outcome of 150 babies following the treatment with letrozole or letrozole and gonadotropins. Fertil Steril 2005;84:S95


